akraniM
akraniM

Recent selected abstracts

 

Mark Christie, Manasi Nandi, Yanika Borg, et al. Mathematical Modelling of Heart Rate Changes in the Mouse. Report on a problem studied at the UK Mathematics-in-Medicine Study Group NC3Rs Study Group 2013. http://www.maths-in-medicine.org/uk/2013-nc3rs/heart-rate/report.pdf

 

Philip J Aston, Manasi Nandi, Mark I Christie, Ying H Huang. Comparison of Attractor Reconstruction and HRV Methods for Analysing Blood Pressure Data. Computing in Cardiology 2014, Volume 41, p437. http://www.cinc.org/archives/2014/pdf/0437.pdf

 

Recent peer reviewed publications

 

Pawsey S, Wood M, Browne H, Donaldson K, Christie M & Warrington S. Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers.

Drugs R D. 16(2): 181-91. 2016

 

Massey AJ, Stokes S, Browne H, Foloppe N, Fiumana A, Scrace S, Fallowfield M, Bedford S, Webb P, Baker L, Christie M, Drysdale MJ & Wood M.  Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design. Oncotarget. 6 (34):35797-812, 2015.

 

Dubey R, Martini LG, Christie M. Dual-acting subcutaneous microemulsion formulation for improved migraine treatment with zolmitriptan and diclofenac: Formulation and in vitro-in vivo characterisation. AAPS J. 16(2): 214-20, 2014.

 

Webb A, Johnson A, Fortunato M, Platt A, Crabbe T, Christie MI, Watt GF, Ward SG & Jopling LA.  Evidence for PI3K-dependent migration of Th17-polarized cells in response to CCR2 and CCR6 agonists.  J. Leuk. Biol. 84 (4): 1202-12, 2008.

 

Walters I, Austin C, Austin R, Bonnert R, Cage P, Christie M, Ebden M, Gardiner S, Grahames C, Hill S, Hunt F, Jewell R, Lewis S, Martin I, Nicholls D & Robinson D.  Evaluation of a series of bicyclic CXCR2 antagonists.  Biorg. & Med. Chem. Lett. 18: 798-803, 2008

 

Jopling LA, Watt GF, Fisher S, Birch H, Coggon S, Christie MI.  Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay.

Br. J. Pharmacol. 152(8):1260-71, 2007

 

Hunt F, Austin C, Austin R, Bonnert R, Cage P, Christie J, Christie M, Dixon C, Hill S, Jewell R, Martin I, Robinson D, Willis P.  SAR studies on thiazolo[4,5-d]pyrimidine based CXCR2 antagonists involving a novel tandem displacement reaction. Bioorg. Med. Chem. Lett.17 (10):2731-34, 2007

 

Werry TD, Christie MI, Dainty IA, Wilkinson GF, Willars GB.  Ca(2+) signalling by recombinant human CXCR2 chemokine receptors is potentiated by P2Y nucleotide receptors in HEK cells. Br. J. Pharmacol. 135(5):1199-20, 2002

 

Carollo M, Getting SJ, Delaney S, Christie MI, Perretti M. Characterization of CXC and CC chemokine expression in a murine model of chronic granuloma. Inflamm. Res. 51(2):110-1, 2002

 

Carollo M, Hogaboam CM, Kunkel SL, Delaney S, Christie MI, Perretti M. Analysis of the temporal expression of chemokines and chemokine receptors during experimental granulomatous inflammation: role and expression of MIP-1alpha and MCP-1. Br. J. Pharmacol. 134(6):1166-79, 2001 

 

Ajuebor MN, Flower RJ, Hannon R, Christie M, Bowers K, Verity A, Perretti M.

Endogenous monocyte chemoattractant protein-1 recruits monocytes in the zymosan peritonitis model.  J. Leuc. Biol. 63 (1): 108-16, 1998

 

Christie MI & Smith GW.  Cardiovascular and renal hemodynamic effects of A-68930 in the conscious dog: a comparison with fenoldopam. J. Pharm. Exp. Ther. 268(2): 565-70, 1994